PANACEA BIOTEC LTD. - 531349 - Disclosure of Voting results of EGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Panacea Biotec Ltd has informed BSE regarding the details of Voting results of EGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here PANACEA BIOTEC LTD. - 531349 - Details Of The Voting Results Pursuant To Regulation 44(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is in continuation of our earlier letter dated February 26, 2022 along with Proceedings of the Extraordinary General Meeting of the Company held on February 26, 2022 and also informing that the detailed voting results of the business transacted at the EGM, as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") shall be submitted to you upon receipt of Scrutinizer''s Report. We would like to inform you that as per the Scrutinizer''s Report, the resolution mentioned in the EGM notice has been passed by the shareholders with requisite majority. Pursuant to Regulation 44(3) of the SEBI LODR Regulations read with amended Rule 20 of Companies (Management and Administration) Rules, 2015, the detailed voting results along with the Scrutinizer''s Report is enclosed herewith. This is for your information and record. Kindly acknowledge the receipt. PANACEA BIOTEC LTD. - 531349 - Proceedings Of The Extraordinary General Meeting Held On February 26, 2022
Pursuant to the provisions of Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), please find enclosed herewith the proceedings of the Extraordinary General Meeting ("EGM") of the Company held on Saturday, February 26, 2022 at 11 :30 A.M. through Video Conferencing ("VC"). The detailed voting results of the business transacted at the EGM as set out in the EGM Notice along with the consolidated Scrutinizer''s Report as required under Regulation 44 of the SEBI LODR Regulations shall be submitted in due course of time. This is for your information and record please.
Panacea Biotec, THSTI tie up to make broad Covid vax, trials in 15-18 mths
If things go according to plan this India-made vaccine could hit the market within the next two to three years PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Panacea Biotec Ltd. is delighted to inform that CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched in March 2021, to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other Betacoronaviruses. CEPI will partner with a consortium comprised of the Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology, Government of India and Panacea Biotec, to develop vaccine candidates that could provide broad protection against SARS-Cov-2 variants and other Betacoronaviruses. CEPI will provide funding of up to $12.5m to support the development of multi-epitope, nanoparticle-based vaccine candidates and advance the manufacturing process. A copy of the Press Release being issued to the media, etc. in this regard is enclosed herewith. PANACEA BIOTEC LTD. - 531349 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
In continuation to our letter dated January 18, 2022 intimating the loss of original share certificate and pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that since the shares have already been transferred to Investor Education and Protection Fund Authority (IEPF Authority), therefore, the Company will not issue any duplicate share certificate in lieu thereof. However, after complying with all the necessary formalities, the Company has issued Entitlement Letter for proceeding him to claim back shares as well as dividend from the IEPF Authority PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated February 14, 2022 for approving the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company for the Quarter and Nine months ended December 31, 2021 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of the Extract of Statement of aforesaid Unaudited Financial Results published in the newspapers on February 15,2022.
PANACEA BIOTEC LTD. - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31, 2021
We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. February 14, 2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and nine months ended December 31, 2021. Pursuant to Regulation 47(1)(b) of SEBI LODR Regulations, the Extract of Statement of above said financial results for the quarter and nine months ended December 31, 2021 in the Format as prescribed in Annexure I of SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05.07.2016 is being sent for publication in newspapers. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 04:00 P.M. We request you to kindly bring the above information to the notice of your members.
Serum Institute of India pares stake in Panacea Biotec, stock locked in lower circuit
SII sold a 0.58% stake in the company. As of December 2021, its stakeholding was at 8.59%